Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Inclusion Criteria:

Patients must have relapsed or primary refractory lymphoid malignancy (including B-cell, T-cell, or Hodgkin lymphoma), or multiple myeloma; other transplant eligible diagnoses (e.g. germ cell tumor) can be included with principal investigator (PI) approval
World Health Organization (WHO) classification of patients' malignancies must be provided
Patients with lymphoid malignancies must have a computed tomography (CT) of chest, abdomen, and pelvis within six weeks of enrollment; patients with evidence of lymphadenopathy in the neck must have a CT of neck
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Absolute neutrophil count (ANC) >= 1,500/mm^3
Platelets >= 100,000/mm^3 (without transfusion or growth factor support)
Creatinine clearance (CrCl) greater than 50/ml per minute (all tests must be performed within 28 days prior to registration)
Total bilirubin < 1.5 times upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal
All patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines
Adequate venous access plan in place for apheresis procedure
Three or fewer prior myelotoxic treatment regimens (specific regimens include ifosfamide, carboplatin and etoposide [ICE]; cisplatin, cytarabine, and dexamethasone [DHAP]; methotrexate [MTX]/high-dose cytarabine [HiDAC]; cyclophosphamide, vincristine, doxorubicin, and dexamethasone [hyperCVAD]; bortezomib, thalidomide, dexamethasone and 4-day continuous infusions of cisplatin, doxorubicin, cyclophosphamide, and etoposide [VTD-PACE])

Exclusion Criteria:

Patients known positive for human immunodeficiency virus (HIV), or infectious hepatitis type B or C
Pregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Greater than six prior cycles of lenalidomide therapy
Patients who have previously demonstrated resistance to bendamustine therapy (i.e. no response or progression w/in 6 months)
Fludarabine or other nucleoside analog (except gemcitabine or cytarabine) therapy within 24 months of registration; patients with limited exposure to fludarabine/other nucleoside analog therapy within 24 months may be considered eligible with review and approval by the PI or Co-PI prior to study entry
Symptomatic cardiopulmonary disease
Prior autologous or allogeneic transplantation
Prior radioimmunotherapy within 12 weeks of registration
Prior failed (< 5 x 10^6 CD34/kg) PBSC collection due to inability to mobilize stem cells
Prior pelvic or spinal irradiation
Previous systemic chemotherapy/immunotherapy within 3 weeks before study entry
Concurrent use of other anti-cancer agents or experimental treatments
Known allergy or intolerance to bendamustine, mannitol, GCSF or dexamethasone
More than 3 cycles of myelotoxic salvage chemotherapy within the past 4 months (specific regimens include ICE, DHAP, MTX/HiDAC, hyperCVAD, VTD-PACE)